Register
Login:
Share:
Email Facebook Twitter

Add Immupharma to quick picks

Immupharma Share Price (IMM)



Share Price Information for Immupharma (IMM)


Share Price: 55.50Bid: 55.00Ask: 56.00Change: 1.50 (+2.78%)Riser - Immupharma
Spread: 1.00Spread as %: 1.82%Open: 54.00High: 55.50Low: 54.00Yesterday’s Close: 54.00

Immupharma Plc Ord 10P

Immupharma is listed in the FTSE AIM All-Share
Immupharma is part of the Pharmaceuticals & Biotechnology sector






Share Price SpacerPrice
55.50

Share Price SpacerBid
55.00

Share Price SpacerAsk
56.00

Share Price SpacerChange
2.78%1.50

Share Price SpacerVolume
135,263

Share Price SpacerOpen
54.00

Share Price SpacerHigh
55.50

Share Price SpacerLow
54.00

Share Price SpacerClose
54.00

Share Price SpacerCurrency
GBX


Currency Issue Country Shares in Issue Market Capitalisation Market Size
GBX GB 88.62m £49.19m 5,000

52 Week High 66.00 52 Week High Date 3-NOV-2014
52 Week Low 41.50 52 Week Low Date 9-JUN-2014

# Trades Vol. Sold Vol. Bought PE Ratio Earnings Dividend Yield
8 10,000 37,036 -12.279 -4.52 0.00 0.00




Date
Time
Trade Prc
Volume
Buy/Sell
Bid
Ask
Value
 

24-Nov-14
08:59:19
54.00
-5,000
Sell* 
55.00
56.00
-2,700
Trade Type:
Ordinary
Deletion
Late reported

25-Nov-14
14:25:16
55.50
88,227
 
55.00
56.00
48.97k
Trade Type:
Ordinary

25-Nov-14
14:05:36
55.02
3,000
Sell* 
55.00
56.00
1,651
Trade Type:
Ordinary


*Buys and Sells are calculated on the difference between the trade price and the current mid price. As such, they can occasionally be incorrect.

View more Immupharma trades >>

Directors Deals for Immupharma (IMM)
Trade DateActionNotifierPriceCurrencyAmountHolding
24-Jan-13Sell
Trade Notifier Information for Immupharma
Ajay Agrawal held the position of Non-Executive Director at Immupharma at the time of this trade.
 Ajay Agrawal
57GBX62,1690
24-Jan-12Buy
Trade Notifier Information for Immupharma
Ajay Agrawal held the position of Non-Executive Director at Immupharma at the time of this trade.
 Ajay Agrawal
80GBX62,1690
23-Jan-12Buy
Trade Notifier Information for Immupharma
Franco Di Muzio held the position of Non-Executive Director at Immupharma at the time of this trade.
 Franco Di Muzio
81GBX60,9500
View more Immupharma directors dealings >>

Date/Time
Author
Subject
Share Price
Opinion
Today 21:19
Goyathlay
Woodford
55.50
No Opinion

Boom (and Timbo from ADVFN) brought to our attention that Neil Woodford is starting a small cap biotech fund. This is another link to the story: http://tinyurl.com/oscndp9 It prompted me to look at the constituents of his existing Equity Income Fund . (you can do this by registering on his website) The top 15 are mainly large cap income players consisting of cigarettes and bombs ;) After that there are about 25 small cap biotech companies out of a remaining 57. A very high proportion you may agree. The exact constituents of his new fund will be fascinating. Leas: thanks, appreciated.
Today 20:49
leas
RE: Thoughts
55.50
No Opinion

Goy, great post as usual. I have been invested for about 2 years but I'm sure if I was invested for the last 5 then I would be very sceptical of the BoD and their approach to business. I suspect their focus is placed elsewhere and investor sentiment very low on their list. However, I do think if the trials are a success then 'word of mouth' will promote the treatment. A close family member has had kidney disease for most of his life and had a transplant about 15 years ago. He has remained fit and healthy throughout but is living in hope that improved drugs come online to help delay the inevitable.
Today 20:34
leas
RE: Leas ,just in passing!
55.50
No Opinion

Yes, I had noticed. Sub penny shares tend do that on a regular basis. However, I guess you know from REM. Showing your hand yet again as a hypocrite in relation to ramping are you willing to participate in WH's Christmas charity lottery. Be nice to share some of your wealth to a charity of your choice. I'm surprised my comment got under your skin so much. You did post 'end of' which I took as subject closed but your ego seems to have got the better of you. atb leas.... end of. :)
Today 19:26
Goyathlay
Thoughts
55.50
No Opinion

It is worth reinforcing that Benlysta is NOT licensed as monotherapy. Thus whatever side-effects it provokes will be IN ADDITION to the far from benign side-effect profile of any concomitant steroids, antimalarials, immunosuppressants or NSAIDS. Similarly, it is not, as far as I know, envisaged that Lupuzor will be monotherapy. The same therefore applies. Of course, there may eventually be a tapering-off of other medication, but any eventual monotherapy would need confirmation by Phase IV trials or would be an off-label use etc. Any cost advantage will not be $38,000 per year vs $15,000 per year but '$38,000 + the drug bill for existing therapy' vs ' $15,000 plus the drug bill for existing therapy'. Although cheap generic versions are available for the vast majority of these concomitant drugs, Boom's piece the other day on healthcare costs in the US suggest that the raw materials are but one element of the cost. Similarly, patient convenience would appear to be superior for Lupuzor but there would still presumably be some biochem. testing and thus attendance at clinic. Again, this would be in addition to the monitoring already required for the antimalarials and immunosuppressants etc. For example, the immunosuppressant Azathioprine which requires weekly blood counts during the first 8/52 and then monthly thereafter. Not cheap. My concern with Lupuzor is that no progress, for one reason or another, has been made in the clinic since February 2009. Thus 6 years will have elapsed. Should patients be stabilised on Benlysta or Epratuzumab and are enjoying SOME benefit it would require more evidence of superior efficacy and/or a greater price differential for Lupuzor to DISPLACE them as ESTABLISHED therapy. Persuading patients whose Lupus had previously been uncontrolled for decades and had received some benefit to suddenly try another new drug might be difficult. Benlysta: http://tinyurl.com/mhad3pw This oldish paper gives quite a succinct summary of the different mechanisms of action of all the protagonists. http://tinyurl.com/lmwr9l2
Today 18:38
TurnaShilling
Leas ,just in passing!
55.50
No Opinion

Thank you for Hi-Liting ( endorsing) my post ref:- STG . S.P is UP 8-53% Today !!!
Today 16:28
sicilian_kan
leas
55.50
No Opinion

It will matter if the results are similar. Agree regarding the end game. That any outcome should be in our favour (CRO/Pharma) is a key attraction here.

Share prices shown are taken at time of message posting.
Thread ViewThread View
View more share chat for Immupharma (IMM) >>
Please Login or Register to post messages

Share Trading BrochureRequest your Free brochures on share dealing, spread betting and CFDs




Sign up for Live Prices


CD02WL.001.081313
Home  |  Contact Us  |  About Us  |  Careers  |  Advertise with Us  |  Sitemap  |  Terms & Conditions  |  Cookies  |  Privacy


Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.